All Blogs

Jun 15, 2017

Sanofi investing around $2B into biologics production over next 3 years Following the recent approval of two new biologics, Dupixent and Kevzara, and a pipeline stuffed full of large-molecule drugs, Sanofi will invest as much as €2 billion on its biologics manufacturing network over the next several years. The discl...

Jun 14, 2017

Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. Up to 30 percent of adult acute lymphoblastic leukemia or ALL patients have Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients often ...

Jun 13, 2017

J&J's Invokana matches Jardiance's 14% reduction in major CV events There’s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits—and amputation risks—along with it. In a cardiovascular outcomes trial, Johnson & Johnson's Invokana matched up to Eli Lilly and Boehringer...

Jun 08, 2017

AstraZeneca offloads headache drug Zomig to Grünenthal to raise $300M cash AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company continues to struggle and so will sell yet another asset to raise cash while CEO Pascal Soriot works t...

Jun 07, 2017

In the quest for personalized therapies, most research has focused on how an individual’s genome controls their body’s responses to drugs. However, there is increasing evidence that a person’s unique microbiome — the population of bacteria and other microbes that live in their body — can be key to determining whethe...

Jun 06, 2017

Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—a...

Jun 02, 2017

Tesaro and its new med Zejula are on the block, but bidders aren't rushing in Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med ...

May 31, 2017

Researchers at Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk. Animal studies reveal it to be just as effective as the biological drugs currently in clinical use. Surfactant revolutionised the care of p...

May 30, 2017

Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis (IPF) market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October 2014. And this week, both drugmak...

May 29, 2017

Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30.  In this condition, patients progressively lose their skin color, mostly in patches. The patches ...